Amgen offer update on Aranesp for anemic patients and Nanogen issued patent for method of monitoring PCR using fluorescent energy transfer.

0 Comments | M2 Presswire, July, 2005

M2 PRESSWIRE-7 July 2005-US Financial Network: Amgen offer update on Aranesp for anemic patients and Nanogen issued patent for method of monitoring PCR using fluorescent energy transfer(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:07072005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU).

Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today it was issued Patent No. 6,911,310, "Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system" by the U.S. Patent and Trademark Office. Amgen Inc. (NASDAQ: AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)